CA2701537A1 - Compositions for treatment of tumors by direct administration of a radioisotope - Google Patents
Compositions for treatment of tumors by direct administration of a radioisotope Download PDFInfo
- Publication number
- CA2701537A1 CA2701537A1 CA2701537A CA2701537A CA2701537A1 CA 2701537 A1 CA2701537 A1 CA 2701537A1 CA 2701537 A CA2701537 A CA 2701537A CA 2701537 A CA2701537 A CA 2701537A CA 2701537 A1 CA2701537 A1 CA 2701537A1
- Authority
- CA
- Canada
- Prior art keywords
- radioisotope
- composition
- bone
- administration
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 53
- 238000011282 treatment Methods 0.000 title claims abstract description 39
- 210000001519 tissue Anatomy 0.000 claims abstract description 52
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 45
- 208000018084 Bone neoplasm Diseases 0.000 claims abstract description 29
- 238000009472 formulation Methods 0.000 claims abstract description 19
- 206010005949 Bone cancer Diseases 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 15
- 239000002738 chelating agent Substances 0.000 claims abstract description 14
- 206010068771 Soft tissue neoplasm Diseases 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 20
- 230000002285 radioactive effect Effects 0.000 claims description 18
- 239000011230 binding agent Substances 0.000 claims description 13
- KZUNJOHGWZRPMI-AKLPVKDBSA-N samarium-153 Chemical group [153Sm] KZUNJOHGWZRPMI-AKLPVKDBSA-N 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 11
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 11
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical group [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 11
- RCXMQNIDOFXYDO-UHFFFAOYSA-N [4,7,10-tris(phosphonomethyl)-1,4,7,10-tetrazacyclododec-1-yl]methylphosphonic acid Chemical compound OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1 RCXMQNIDOFXYDO-UHFFFAOYSA-N 0.000 claims description 10
- 229910052751 metal Inorganic materials 0.000 claims description 9
- 239000002184 metal Substances 0.000 claims description 9
- 230000005258 radioactive decay Effects 0.000 claims description 9
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 6
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 6
- -1 Yb-175 Chemical compound 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 4
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 4
- 239000002002 slurry Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 21
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 description 28
- 239000007924 injection Substances 0.000 description 28
- 230000005855 radiation Effects 0.000 description 19
- 238000002725 brachytherapy Methods 0.000 description 14
- 229940120146 EDTMP Drugs 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 210000002307 prostate Anatomy 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 210000000689 upper leg Anatomy 0.000 description 10
- 206010061289 metastatic neoplasm Diseases 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- NFDRPXJGHKJRLJ-UHFFFAOYSA-N edtmp Chemical compound OP(O)(=O)CN(CP(O)(O)=O)CCN(CP(O)(O)=O)CP(O)(O)=O NFDRPXJGHKJRLJ-UHFFFAOYSA-N 0.000 description 8
- 229940121896 radiopharmaceutical Drugs 0.000 description 8
- 239000012217 radiopharmaceutical Substances 0.000 description 8
- 230000002799 radiopharmaceutical effect Effects 0.000 description 8
- 238000001959 radiotherapy Methods 0.000 description 8
- 230000001394 metastastic effect Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 241000700157 Rattus norvegicus Species 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 239000013522 chelant Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical compound OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 238000005553 drilling Methods 0.000 description 4
- 230000005670 electromagnetic radiation Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 150000002739 metals Chemical class 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- CIOAGBVUUVVLOB-OUBTZVSYSA-N strontium-89 Chemical compound [89Sr] CIOAGBVUUVVLOB-OUBTZVSYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 229960001484 edetic acid Drugs 0.000 description 3
- 239000004081 narcotic agent Substances 0.000 description 3
- 229960003330 pentetic acid Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 229910052727 yttrium Inorganic materials 0.000 description 3
- NKIJBSVPDYIEAT-UHFFFAOYSA-N 1,4,7,10-tetrazacyclododec-10-ene Chemical compound C1CNCCN=CCNCCN1 NKIJBSVPDYIEAT-UHFFFAOYSA-N 0.000 description 2
- URDCARMUOSMFFI-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(2-hydroxyethyl)amino]acetic acid Chemical compound OCCN(CC(O)=O)CCN(CC(O)=O)CC(O)=O URDCARMUOSMFFI-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 229940122361 Bisphosphonate Drugs 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229910052689 Holmium Inorganic materials 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 229910052772 Samarium Inorganic materials 0.000 description 2
- YDONNITUKPKTIG-UHFFFAOYSA-N [Nitrilotris(methylene)]trisphosphonic acid Chemical compound OP(O)(=O)CN(CP(O)(O)=O)CP(O)(O)=O YDONNITUKPKTIG-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 150000004663 bisphosphonates Chemical class 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 229940090960 diethylenetriamine pentamethylene phosphonic acid Drugs 0.000 description 2
- DUYCTCQXNHFCSJ-UHFFFAOYSA-N dtpmp Chemical compound OP(=O)(O)CN(CP(O)(O)=O)CCN(CP(O)(=O)O)CCN(CP(O)(O)=O)CP(O)(O)=O DUYCTCQXNHFCSJ-UHFFFAOYSA-N 0.000 description 2
- XOHQAXXZXMHLPT-UHFFFAOYSA-N ethyl(phosphonooxy)phosphinic acid Chemical compound CCP(O)(=O)OP(O)(O)=O XOHQAXXZXMHLPT-UHFFFAOYSA-N 0.000 description 2
- 210000002767 hepatic artery Anatomy 0.000 description 2
- KJZYNXUDTRRSPN-OUBTZVSYSA-N holmium-166 Chemical compound [166Ho] KJZYNXUDTRRSPN-OUBTZVSYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002331 radioactive microsphere Substances 0.000 description 2
- 229910052761 rare earth metal Inorganic materials 0.000 description 2
- 150000002910 rare earth metals Chemical class 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 229940006509 strontium-89 Drugs 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- JKTORXLUQLQJCM-UHFFFAOYSA-N 4-phosphonobutylphosphonic acid Chemical compound OP(O)(=O)CCCCP(O)(O)=O JKTORXLUQLQJCM-UHFFFAOYSA-N 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229910052692 Dysprosium Inorganic materials 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 229910052765 Lutetium Inorganic materials 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 208000036631 Metastatic pain Diseases 0.000 description 1
- 229940127048 Metastron Drugs 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 229910018828 PO3H2 Inorganic materials 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 208000005250 Spontaneous Fractures Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229910052769 Ytterbium Inorganic materials 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- IMUDHTPIFIBORV-UHFFFAOYSA-N aminoethylpiperazine Chemical compound NCCN1CCNCC1 IMUDHTPIFIBORV-UHFFFAOYSA-N 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000007470 bone biopsy Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940127042 diagnostic and therapeutic radiopharmaceutical Drugs 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000011347 external beam therapy Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004995 male reproductive system Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- SZZACTGRBZTAKY-NKNBZPHVSA-F pentasodium;samarium-153(3+);n,n,n',n'-tetrakis(phosphonatomethyl)ethane-1,2-diamine Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[153Sm+3].[O-]P([O-])(=O)CN(CP([O-])([O-])=O)CCN(CP([O-])([O-])=O)CP([O-])([O-])=O SZZACTGRBZTAKY-NKNBZPHVSA-F 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940087876 quadramet Drugs 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- AHBGXTDRMVNFER-FCHARDOESA-L strontium-89(2+);dichloride Chemical compound [Cl-].[Cl-].[89Sr+2] AHBGXTDRMVNFER-FCHARDOESA-L 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940127044 therapeutic radiopharmaceutical Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
- A61K51/048—DTPA (diethylenetriamine tetraacetic acid)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99785607P | 2007-10-05 | 2007-10-05 | |
| US99787307P | 2007-10-05 | 2007-10-05 | |
| US60/997,873 | 2007-10-05 | ||
| US60/997,856 | 2007-10-05 | ||
| PCT/US2008/002026 WO2009045230A1 (en) | 2007-10-05 | 2008-02-15 | Compositions for treatment of tumors by direct administration of a radioisotope |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2701537A1 true CA2701537A1 (en) | 2009-04-09 |
Family
ID=40526495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2701537A Abandoned CA2701537A1 (en) | 2007-10-05 | 2008-02-15 | Compositions for treatment of tumors by direct administration of a radioisotope |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP2195036A4 (es) |
| JP (1) | JP2010540627A (es) |
| CA (1) | CA2701537A1 (es) |
| WO (1) | WO2009045230A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007008232A2 (en) | 2004-09-03 | 2007-01-18 | Board Of Regents, The University Of Texas System | Locoregional internal radionuclide ablation of abnormal tissues. |
| DOP2010000279A (es) * | 2009-09-18 | 2012-06-15 | Sari Asher Llc | Composiciones radiofarmaceuticas no-coloidales sin sellar y metodos para el tratamiento de tejido anormal |
| CN102859608B (zh) * | 2010-03-09 | 2016-08-03 | 库里昂股份有限公司 | 使用离子特异性介质的同位素特异性分离和玻璃化 |
| US9714457B2 (en) | 2012-03-26 | 2017-07-25 | Kurion, Inc. | Submersible filters for use in separating radioactive isotopes from radioactive waste materials |
| GB2490317A (en) * | 2011-04-19 | 2012-10-31 | Dspi Ltd | Radioactive solution undergoing in situ precipitation at a tumour site for cancer therapy |
| WO2013096776A2 (en) * | 2011-12-21 | 2013-06-27 | Iso Therapeutics Group Llc | Radioactive compositions and methods for their therapeutic use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4849209A (en) * | 1985-06-07 | 1989-07-18 | Cadema Medical Products, Inc. | Treatment of arthritis, including rheumatoid arthritis with 166 Holmium radionuclide |
| US4915932A (en) * | 1987-10-14 | 1990-04-10 | Australian Nuclear Science & Technology Organisation | Macroaggregates for radiation synovectomy |
| US20030003048A1 (en) * | 2001-04-26 | 2003-01-02 | Chun Li | Diagnostic imaging compositions, their methods of synthesis and use |
| AU2003299565A1 (en) * | 2002-11-27 | 2004-06-23 | Board Of Regents, The University Of Texas System | Radiopharmaceuticals and radioactive microspheres for locoregional ablation of abnormal tissues |
| US8388955B2 (en) * | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| WO2007008232A2 (en) * | 2004-09-03 | 2007-01-18 | Board Of Regents, The University Of Texas System | Locoregional internal radionuclide ablation of abnormal tissues. |
| AU2005290229A1 (en) * | 2004-09-24 | 2006-04-06 | Biosphere Medical, Inc. | Microspheres capable of binding radioisotopes, optionally comprising metallic microparticles, and methods of use thereof |
-
2008
- 2008-02-15 EP EP08725637A patent/EP2195036A4/en not_active Withdrawn
- 2008-02-15 WO PCT/US2008/002026 patent/WO2009045230A1/en active Application Filing
- 2008-02-15 CA CA2701537A patent/CA2701537A1/en not_active Abandoned
- 2008-02-15 JP JP2010527928A patent/JP2010540627A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010540627A (ja) | 2010-12-24 |
| EP2195036A1 (en) | 2010-06-16 |
| EP2195036A4 (en) | 2011-03-09 |
| WO2009045230A1 (en) | 2009-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2268888T3 (es) | El uso de radio-223 para dirigirse a tejidos calcificados para paliacion del dolor y terapia de cancer oseo. | |
| Farhanghi et al. | Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer | |
| JP5219325B2 (ja) | 骨標的錯体 | |
| US10918746B2 (en) | Radioactive compositions and methods for their therapeutic use | |
| AU2001267734A1 (en) | Radiotherapy | |
| CA2701537A1 (en) | Compositions for treatment of tumors by direct administration of a radioisotope | |
| WO2011149844A1 (en) | Delivery of high dose therapeutic radioisotopes to bone | |
| US20120251442A1 (en) | Methods for Treatment of Tumors by Direct Administration of a Radioisotope | |
| US20090252675A1 (en) | Radionuclide Therapy for Urinary Bladder Cancer | |
| US8709380B1 (en) | Targeting agents for enhancing radiation therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |
Effective date: 20150317 |